<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483402</url>
  </required_header>
  <id_info>
    <org_study_id>58/15.02.2018/5103</org_study_id>
    <nct_id>NCT03483402</nct_id>
  </id_info>
  <brief_title>Micropulse Laser Trabeculoplasty as Adjunctive Treatment in Patients With Pseudoexfoliation Glaucoma</brief_title>
  <official_title>Study of the Efficacy of a Single Session Micropulse Laser Trabeculoplasty as an Adjunctive Measure in Decreasing Intraocular Pressure in Patients Suffering From Pseudoexfoliation Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of a single session of micropulse laser
      trabeculoplasty (MLT) on cornea in eyes with primary open glaucoma (POAG) and
      pseudoexfoliation glaucoma (PEXG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with PEXG under prostaglandine analogue monotherapy with inadequate IOP control are
      treated with 360-degrees 532nm MLT.

      Patients are evaluated at 1 day, 1 month, 3 months, 6 months and 12 months post-MLT. After
      trabeculoplasty patients are maintained in treatment with the same drug regimen as pre-MLT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-center, one-arm, prospective clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>The change in IOP at 12 months versus baseline and the percentage of patients with ≥20% reduction in IOP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Change in IOP and the percentage of ≥20% IOP reduction at 1, 3 and 6 months after MLT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Pseudoexfoliation Glaucoma</condition>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>PEXG treated with MLT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Micropulse laser trabeculoplasty</intervention_name>
    <description>Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.</description>
    <arm_group_label>PEXG treated with MLT</arm_group_label>
    <other_name>MLT Iridex IQ 532 laser system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with POAG or PEXG under treatment with glaucoma agents requiring additional
             reduction of IOP, age older than 18 years, patients willing to provide informed
             consent to participate in the study and to adhere to the follow-up schedule.

        Exclusion Criteria:

          -  pre-existing corneal pathology or scar, history of any previous ocular surgery or any
             planned ocular surgery during the study, history of prior laser trabeculoplasty,
             end-stage glaucoma with advanced visual field defect, monocular patients, history of
             trauma, and concurrent systemic or topical steroid use

          -  patients unable to present for follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine D Georgakopoulos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Patras, Medical School</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Patras</investigator_affiliation>
    <investigator_full_name>Constantinos D. Georgakopoulos, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Pseudoexfoliation Glaucoma</keyword>
  <keyword>Primary Open-angle Glaucoma</keyword>
  <keyword>Micropulse Laser Trabeculoplasty</keyword>
  <keyword>Intraocular Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

